Egg Freezing (Oocyte Cryopreservation) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Egg freezing, or oocyte cryopreservation, is a fertility preservation technique that uses vitrification—ultra-rapid freezing at -196°C in liquid nitrogen—to preserve unfertilized mature oocytes for future use in IVF. By removing the time pressure on fertility decisions, it allows women to bank eggs while oocyte quality is optimal and use them later when they are ready to conceive.

The procedure begins with ovarian stimulation using injectable gonadotropins (FSH and LH analogs) for 10–14 days to induce multi-follicular development. Follicle growth is monitored by transvaginal ultrasound and serum estradiol every 2–3 days. A trigger injection of hCG or leuprolide acetate is administered when lead follicles reach 18–20 mm, followed by transvaginal oocyte retrieval under conscious sedation 36 hours later. Typically 10–20 mature oocytes are retrieved per stimulation cycle, though yields vary significantly by age and ovarian reserve.

Vitrification achieves 80–90% oocyte survival rates upon thawing, far superior to slow-freeze methods (50–60%). The American Society for Reproductive Medicine (ASRM) removed the 'experimental' label from oocyte cryopreservation in 2012, recognizing its clinical maturity. Key indications include: social fertility preservation (elective banking for women delaying childbearing), oncofertility before gonadotoxic chemotherapy or pelvic radiation, preservation for BRCA1/BRCA2 mutation carriers prior to prophylactic oophorectomy, unexplained poor ovarian response anticipation, and transgender men before initiating hormone therapy that impairs ovarian function. Emergency random-start stimulation protocols allow cancer patients to complete egg retrieval within 12–14 days regardless of menstrual cycle phase.

Egg freezing is indicated across a broad spectrum of medical and personal circumstances where preserving reproductive potential is essential or desired. Social fertility preservation is the most common indication: women aged 30–38 who wish to delay childbearing for career, relationship, or personal reasons elect to bank eggs during their peak reproductive years to maintain options when they are ready to conceive.

Oncofertility preservation is a critical medical indication for reproductive-age women diagnosed with breast cancer, lymphoma, leukemia, cervical cancer, or any malignancy requiring gonadotoxic chemotherapy (especially alkylating agents such as cyclophosphamide) or pelvic radiation, both of which cause premature ovarian insufficiency. Urgent referral to a reproductive endocrinologist before cancer treatment begins enables egg retrieval in as little as two weeks.

BRCA1 and BRCA2 mutation carriers who plan prophylactic bilateral salpingo-oophorectomy (PBSO) to reduce ovarian cancer risk benefit enormously from banking eggs before surgery, preserving their only opportunity for genetic parenthood. Women with Turner syndrome or other conditions predisposing to premature ovarian insufficiency should be counseled about fertility preservation early, as ovarian reserve declines rapidly. Primary ovarian insufficiency (POI) patients with residual follicles may attempt egg freezing, though stimulation response is often poor and should be discussed with realistic expectations. Planned ovarian surgery for endometriosis or borderline ovarian tumors may further reduce ovarian reserve and warrants pre-operative fertility preservation counseling.

Ideal candidates for egg freezing are women younger than 35 years with adequate ovarian reserve defined by AMH ≥1.0 ng/mL and antral follicle count (AFC) of ≥5–7 per ovary on baseline ultrasound. Success rates decline significantly with age: at age 35, live birth probability per thaw cycle using own eggs is 25–35%; at 38–40, it falls to 15–25%; above 40, outcomes are substantially lower at 5–15%. Women should be counseled clearly that egg freezing is not a guarantee of future pregnancy and that younger egg banking yields substantially better outcomes.

Recommended egg banking targets are 15–20 mature oocytes for women under 35 to achieve a reasonable probability of one live birth. Older women or those with diminished ovarian reserve may require multiple stimulation cycles to accumulate sufficient numbers. Cumulative live birth probability increases with each additional banked oocyte.

Pre-cycle workup includes: AMH and antral follicle count (ovarian reserve assessment), Day 3 FSH and estradiol, baseline pelvic ultrasound, complete blood count, infectious disease screening (HIV, hepatitis B, hepatitis C, CMV), and thyroid function tests. Genetic counseling is recommended for BRCA carriers and women with hereditary conditions. Women with PCOS face elevated OHSS risk and should be offered antagonist protocols with GnRH agonist trigger and freeze-all strategy. Cancer patients require oncofertility consultation within 24–48 hours of diagnosis; random-start stimulation protocols and letrozole co-administration (for hormone-sensitive cancers such as breast cancer) are standard in oncofertility settings.

Standard egg freezing protocol: transvaginal baseline ultrasound on day 2–3 of the menstrual cycle confirms absence of ovarian cysts and establishes AFC baseline. Daily subcutaneous FSH injections (150–300 IU, adjusted by individual response) begin on day 2–3, continuing for 10–14 days. Serial monitoring (ultrasound every 2–3 days; oestradiol levels) guides dose adjustment. A GnRH antagonist (cetrorelix, ganirelix) is added from day 6–8 to prevent premature ovulation. When lead follicles reach 17–18 mm mean diameter, dual trigger (hCG + GnRH agonist) or GnRH agonist-alone trigger (in OHSS-risk patients) is administered. Egg retrieval is performed 36 hours later under IV sedation via transvaginal ultrasound-guided follicular aspiration.

Random-start protocols: stimulation can begin at any point in the menstrual cycle — particularly relevant for cancer patients or time-pressured social freezers — with equivalent egg yield compared to conventional day 2–3 start, at the cost of 2–3 extra monitoring days.

Vitrification (ultra-rapid cryopreservation): retrieved MII oocytes are equilibrated in cryoprotectant solutions then plunged into liquid nitrogen at minus 196°C within seconds — eliminating ice crystal formation that damaged eggs with older slow-freeze methods. Survival rates exceed 90% with vitrification. Eggs are stored in liquid nitrogen vapour dewars indefinitely. OSCA (Oocyte Sensitivity to Cryopreservation Assessment) scoring systems select mature, spindle-intact oocytes for best post-thaw outcomes. Minimal stimulation IVF (milder stimulation with fewer eggs but lower cost per cycle) is an option for those who cannot commit to full stimulation.

Vitrification has transformed oocyte cryopreservation outcomes dramatically. Current survival rates upon thawing are 80–90% for vitrified oocytes versus 50–60% for slow-frozen eggs, bringing frozen egg outcomes to parity with fresh. Fertilization rates of thawed oocytes using ICSI are 70–80%, comparable to fresh oocytes. Clinical pregnancy rates per thaw cycle are age-dependent: women under 35 achieve 35–45% per transfer; ages 35–37, 25–35%; ages 38–40, 15–25%; above 40, 5–15%. Donor oocyte programs using vitrified donor eggs report live birth rates of 40–55% per thaw cycle regardless of recipient age.

The most critical clinical benefit is oncofertility: egg freezing enables cancer survivors to have biologically related children after completing treatment. Multiple large registry studies demonstrate no increased risk of chromosomal abnormalities or birth defects in children born from frozen-thawed oocytes compared to fresh IVF cycles—a vital assurance for patients and clinicians.

For elective social preservation, women who bank eggs before age 35 and use them before age 40 achieve outcomes comparable to fresh IVF at that younger age, effectively preserving their younger reproductive potential. A meta-analysis using SART data shows that banking 15–20 mature oocytes before age 36 yields approximately 70–80% cumulative live birth probability. Psychological benefits—significantly reduced reproductive anxiety, increased sense of agency over family planning—are consistently documented in qualitative and quantitative studies of women who undergo egg freezing, regardless of whether they ultimately use the banked eggs.

Ovarian hyperstimulation syndrome (OHSS) is the most significant medical complication of egg freezing stimulation. Mild-to-moderate OHSS (pelvic discomfort, bloating, nausea, mild ascites) occurs in 10–20% of cycles and resolves with conservative management. Severe OHSS—characterized by massive ascites, pleural effusion, hemoconcentration, electrolyte imbalance, and thromboembolism risk—occurs in 1–3% of cycles and may require hospitalization, intravenous albumin, or paracentesis. Women with PCOS are at substantially higher risk. GnRH antagonist protocols combined with GnRH agonist trigger injection (instead of hCG trigger) reduce severe OHSS risk to near zero while maintaining equivalent egg yields in most patients, and are now standard practice in most freeze-all egg banking cycles.

Oocyte retrieval under transvaginal ultrasound guidance carries a small risk of pelvic bleeding (<1%), pelvic infection (<0.5%), and anesthetic complications. Injury to adjacent structures (bladder, bowel, major blood vessels) is rare but documented in fewer than 0.1% of procedures.

Patients must be counseled that egg freezing does not guarantee a future pregnancy: oocyte survival, fertilization, embryo development, and implantation each involve attrition, and the overall probability of a live birth per frozen egg is approximately 5–7% for women under 35. Financial burden is substantial: multiple cycles are often needed, annual storage fees are ongoing, and future IVF cycle costs add significantly to the total program cost. Emotional challenges of daily injections, frequent monitoring appointments, and the uncertainty of future outcomes should be proactively addressed with psychological support as part of comprehensive fertility preservation care.

Egg retrieval recovery requires 2–4 hours post-procedure monitoring in the clinic before discharge. Mild pelvic discomfort, bloating, and light spotting are expected for 2–5 days. Light activity resumes the following day; strenuous exercise and intercourse should be avoided for 5–7 days. OHSS monitoring continues for 5–10 days after retrieval — weight gain exceeding 2 kg in 24 hours, severe bloating, or reduced urination requires prompt clinical assessment.

Patients receive a post-cycle egg count report — total eggs retrieved, mature (MII) eggs vitrified, and any immature eggs not stored. Storage facility contact is maintained annually to ensure ongoing cryopreservation and update intentions. When ready to use frozen eggs, the thawing-and-fertilisation process involves: egg thaw (survival rate greater than 90%), ICSI fertilisation (conventional IVF insemination is not used for frozen eggs due to zona pellucida hardening), embryo culture to blastocyst, and endometrial preparation for FET. Patients should expect 2–3 IVF stimulation cycles to bank 15–20 mature eggs for a 70–75% cumulative live birth probability if under 35 at time of freezing.

Egg freezing costs include ovarian stimulation medications, monitoring ultrasounds and blood tests, the oocyte retrieval procedure, vitrification laboratory fees, and annual cryostorage. Costs vary substantially by country. In the United States, a single complete stimulation-and-retrieval cycle costs $6,000–$12,000 for the procedure, with fertility medications adding $3,000–$5,000, and annual storage fees of $500–$1,000 per year. Women who require multiple cycles may spend $15,000–$30,000 or more on a comprehensive banking program before future IVF costs.

In India, a complete egg freezing cycle including medications is available at $2,500–$5,000 at accredited fertility centers in Mumbai, Delhi, Bengaluru, and Chennai, with annual storage fees of $200–$500. Thailand offers comparable laboratory quality at $3,000–$6,000 per cycle at JCI-accredited hospitals in Bangkok. Spain charges €3,000–€6,000 per cycle and is a leading European destination, particularly for egg donation programs. Israel has a well-established national fertility program with costs of $2,000–$5,000 per cycle and government subsidy available for oncofertility indications. The UK charges £3,500–£6,000 per cycle privately; NHS funding is limited to specific medical indications. Australia costs AUD $5,000–$9,000 per cycle.

Medical tourists seeking affordable egg freezing should verify laboratory IVF accreditation, embryologist experience with vitrification, documented thaw survival rates, and provisions for returning home with documentation enabling future IVF at another center if needed. Remote monitoring for the stimulation phase at a local clinic followed by travel for retrieval reduces time abroad to approximately 3–4 days.

Embryo cryopreservation (rather than unfertilised egg freezing) is preferred when a partner or donor sperm is available — embryo survival and implantation rates are marginally higher than unfertilised eggs, and embryos can be PGT-A tested before transfer. For women with diminished ovarian reserve producing few eggs per cycle, in vitro maturation (IVM) retrieves immature oocytes from antral follicles with minimal or no stimulation, then matures them in the laboratory — an alternative for PCOS patients at OHSS risk or for whom FSH stimulation is contraindicated.

Ovarian tissue cryopreservation (surgical removal of ovarian cortex, cryopreservation, later reimplantation) is an alternative that preserves ovarian endocrine function and allows multiple natural conception attempts after reimplantation. It is the only option for pre-pubertal cancer patients. For women who decide against fertility preservation, donor egg IVF after premature ovarian insufficiency achieves live birth rates of 55–65% per transfer irrespective of recipient age. Natural conception optimisation (ovulation tracking, lifestyle modification, supplementation) is appropriate for women not yet actively trying but seeking low-intervention approaches.